Nautilus Biotechnology Inc (NAUT)
Nautilus Biotechnology Inc is a development-stage life sciences company focused on building technology to measure and better characterize the proteome in the United States. Its Nautilus Voyager platform is designed as an integrated system that combines instruments, reagents, consumables, and software for protein analysis. The company’s instrument uses high-resolution optical imaging together with fluidics and liquid-handling components to support repeated binding and imaging cycles for identifying proteins in biological samples. Nautilus also supplies single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers for multi-cycle analysis workflows.
The company has research collaborations with Genentech, the Buck Institute, the Allen Institute, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation. Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington. Its common stock is listed on NASDAQ under the symbol NAUT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NAUT
|
$1.73
|
1.9% Upside
|
Fair
|
$4
|
135.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 28, 2026
|
-3.8x
|
1.5x
|
—
|
214.8 M
|
100.9 M
|
11.9%
|
43.9%
|
0.6
|
—
|
90.1%
|
